Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

New inhibitors claimed of RAC-alpha serine/threonine-protein kinase phosphorylation

Feb. 3, 2011

Enrollment started in Aveo Pharma's phase II tivozanib biomarker trial

Feb. 3, 2011

ELGEN-1000-delivered DNA vaccines cleared to enter phase II leukemia trial in U.K.

Feb. 3, 2011

Novel protein kinase inhibitors described at sanofi-aventis

Feb. 3, 2011

Enrollment begins in phase II CP-4126 trial in gemcitabine-refractory pancreatic cancer

Feb. 2, 2011

Hutchison MediPharma begins phase I trial of fruquintinib in China

Feb. 2, 2011

New inhibitors claimed of RAC-alpha serine/threonine-protein kinase phosphorylation

Feb. 2, 2011

Novartis develops novel PI3K-alpha inhibitors

Feb. 2, 2011

Dasatinib is not active in previously treated metastatic colorectal cancer

Feb. 2, 2011

Targeting of CD44 by miRNA-34a suppresses regeneration and metastatic potential of prostate CSCs

Feb. 2, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...